This paper compared cell-free DNA (cfDNA) levels in plasma stored for <5 years and ≥5 years and investigated the association between cfDNA levels and patient age, gender, smoking status, body mass index (BMI), chronic disease, alcohol consumption, and colonoscopy preparation on median cfDNA levels. The effects of cancer stage and metastasis on cfDNA levels in patients with colorectal carcinoma (CRC) was also investigated.
Age-stratified reference intervals unlock the clinical potential of circulating cell-free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer.
Ørntoft MW, Jensen SØ, Øgaard N, Henriksen TV, Ferm L, Christensen IJ, Reinert T, Larsen OH, Nielsen HJ, Andersen CL
Purpose
Conclusion
Plasma stored for ≥5 years had significantly lower levels of cfDNA than plasma stored for <5 years. Multivariate regression analysis showed elevated cfDNA levels were associated with undergoing colonoscopy preparation, patient age, BMI, and increased number of chronic diseases as well as diagnosis with diabetes, heart disease, hypertension, IBD, pulmonary disease, or rheumatoid arthritis. Reduced cfDNA levels were associated with smoking. There was a non-significant trend toward higher cfDNA levels in males than females but there was no effect of number of units of alcohol consumed per week. Patients with CRC had significantly higher cfDNA levels than those without cancer but, when broken down by cancer stage, the difference was only significant for those with stage IV CRC. cfDNA levels were higher in patients with metastatic CRC than those without metastasis and increased with tumor size. Overall survival was negatively associated with cfDNA levels >90% of the age-stratified reference after normalization for gender, BMI, smoking status, alcohol consumption, chronic diseases, and CRC stage. In patients without cancer, overall survival was also negatively associated with patient age, smoking, and presence of three or more chronic diseases. In patients with CRC, overall survival was negatively associated with stage III or IV disease and age.
Studies (1)
Purpose
This study compared cfDNA levels in plasma stored for <5 years and ≥5 years and investigated the association between cfDNA levels and patient age, gender, smoking status, BMI, chronic disease, colonoscopy preparation, and alcohol consumption on median cfDNA levels. The influence of cancer stage and metastasis on cfDNA levels in patients with CRC was also investigated. K2EDTA blood was collected from patients aged 50-75 years. Blood was collected at diagnosis from 889 patients with colorectal cancer, from 1056 patients needing colonoscopy (838 normal results and 218 with adenoma), and from 875 patients who, after screening, did not require a colonoscopy. Plasma was obtained by dual centrifugation at 3000 x g for 10 minutes at 20°C within 2 h of venipuncture. Plasma was stored in cryotubes at -80°C and transferred (details not provided) to a central laboratory and stored until extraction (66-3971 days total). Plasma was spiked with soybean CPP1 DNA. DNA was isolated using the QIAsymphony DSP Circulating DNA Kit and stored at -80°C. CPP1, a B-cell specific VDJ rearranged IgH, and a region of Chromosome 3 were quantified by ddPCR. cfDNA concentration was based on number of copies of Chromosome 3 detected. The extraction efficiency was calculated based on the percent of spiked-in CPP1 recovered. Specimens were considered to have lymphocyte contamination if the B-cell specific VDJ rearrangement was amplified.
Summary of Findings
Three specimens were excluded from analysis: two due to amplification failure and one due to the detection of lymphocyte DNA. Plasma stored for ≥5 years had significantly lower levels of cfDNA than plasma stored for <5 years (P<0.01). The cfDNA yield progressively increased with patient age in patients with CRC with significant differences observed between each group when patient age was binned by decade (P<0.01, all). When only patients who did not undergo colonoscopy were examined, a significant effect of patient age was only observed in patients ≥67 years versus <67 years (P<0.001). Multivariate regression analysis showed elevated cfDNA levels were associated with undergoing colonoscopy preparation (P<0.001), patient age (P<0.001), BMI (P<0.001), and increased number of chronic diseases (P<0.001) as well as diagnosis with diabetes (P<0.001), heart disease (P<0.001), hypertension (P<0.001), IBD (P=0.007), pulmonary disease (P=0.002), or rheumatoid arthritis (P=0.022). Reduced cfDNA levels were associated with smoking (P<0.001). There was a non-significant trend toward higher cfDNA levels in males than females but there was no effect of number of units of alcohol consumed per week. Further analysis revealed significantly higher cfDNA yield in patients with each additional chronic disease from 0-4 (P<0.001, all). Patients with CRC had significantly higher cfDNA levels than those without cancer (P=0.015) but, when broken down by cancer stage, the difference was only significant for those with stage IV CRC (P<0.001). cfDNA levels were higher in patients with metastatic CRC than those without metastasis (P<0.001) and increased with tumor size (P=0.028). Overall survival was negatively associated with cfDNA levels >90% of the age-stratified reference after normalization for age, gender, BMI, smoking status, alcohol consumption, chronic diseases and CRC stage. In patients without cancer, overall survival was also negatively associated with patient age, smoking, and presence of three or more chronic diseases. In patients with CRC, overall survival was negatively associated with stage III or IV disease and patient age.
Biospecimens
FluidPlasmaPreservation Types
FrozenDiagnoses
Diabetes Type 2Irritable Bowel SyndromeCardiovascular DiseaseRheumatoid ArthritisHypertensionNeoplasticBenignNeoplasticCarcinomaNot specifiedPlatforms
DNADigital PCRPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Preaquisition Diagnosis/ patient condition AdenomaCRCDiabetesHeart diseaseHypertensionIBDNon-cancerPulmonary diseaseRheumatoid arthritisPreaquisition Non-invasive procedure type Colonoscopy preparationNo colonoscopy preparationPreaquisition Other drugs 0 units alcohol/week1-7 units alcohol/week15-21 units alcohol/week8-14 units alcohol/week>21 units alcohol/weekNever smokerPrevious smokerSmokerPreaquisition Patient age 50-60 years60-70 years70-80 years<50 years<67 years>67 yearsPreaquisition Patient body mass index 20-2525-3035-40<20>40Preaquisition Patient gender FemaleMalePreaquisition Prognostic factor MetastasisNo metastasisStage I CRCStage II CRCStage III CRCStage IV CRCStorage Storage duration <5 years≥5 years